iMSC
Phase 1Biologic
iMSC is one of 24 biologic programs targeting Mesenchymal Stromal Cells. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Allogeneic Hematopoietic Stem Cell Transplantation
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Dacogen
Sun Pharmaceutical Industries, Inc.Phase 3
Nexavar
BayerPhase 3
Fludara
SanofiPhase 2
Cellcept
RochePhase 2
Tepadina
Jazz PharmaceuticalsPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Mesenchymal Stromal Cells
Mario Negri Institute for Pharmacological ResearchPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 2
Busulfex
Akero TherapeuticsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Mesenchymal Stromal Cells1 trial
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
Recruiting·—·N/A·NCT06321198·12 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for iMSC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- RRuijin Hospital